** Shares of Ascentage Pharma Group International 6855.HK jump 12.3% to HK$43.45, a peak since Jan. 6
** Stock on track for biggest one-day pct rise since Aug. 26, 2024
** Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical 4502.T, said on Tuesday it was targeting a valuation of $1.75 bln in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year
** Ascentage, which is focused on developing and commercializing therapies that target malignancies, is looking to raise $149 mln by offering about 7.3 mln American depositary shares at $20.34 each
** Shares of Takeda Pharmaceutical 4502.T up 0.2%
** Hong Kong's healthcare index .HSCIH slips 0.5% and Hang Seng Index .HSI falls 1.4%
** Ascentage stock soared 66.5% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。